We have recently found a novel fatty acid, ll-keto-9(£),12(iT)-octadecadienoic acid (KOD), that enhances fibrinolytic activity of endothelial cells. The mechanism of action of KOD has been investigated. KOD increased 2-fold the plasmin activity of bovine aortic endothelial cells at 250 jam. The stimulation was dependent on plasminogen and was inhibited by anti-urokinase, whereas KODdid not enhance the urokinase-catalyzed plasminogen activation and the resulting plasmin activity in a cell-free system. Neither the production of urokinase nor the conversion of pro-urokinase to the active, two-chain form was elevated by KOD, but it decreased plasminogen activator inhibitor-1 (PAI-1) activity of cells and inactivated PAI-1 irreversibly in a purified system. These results demonstrated that the KODenhancement of endothelial fibrinolytic activity was mediated, at least in part, by inactivation of PAI-1.
with atherosclerosis and thromboembolism, plasminogen activator inhibitor type 1 (PAI-1) may be dominant in this balance1?2).
PAI-1 belongs to the serpin superfamily3).
Humanmature PAI-1 is a 48-kDa single-chain glycoprotein consisting of 379 amino acids3)4). PAI-1 is produced as an active molecule, but it spontaneously converts to an inactive, latent form5). Latent PAI-1 can be re-activated by exposure to denaturing agents, followed by refolding6). Like other serpins, PAI-1 is thought to associate with the target protease through a bait residue in a reactive site loop. The reactive site loop is partly inserted between strands 3 and 5 of the j8-sheet A of the molecule, and this insertion appears to be required for inhibition7 for 6hours in the presence of 35S protein labeling mixture (50 /iCi/ml) in methionine-free mediumA. After washing with buffer B, cells were scraped in buffer C containing 10 /ig/ml aprotinin and disrupted by sonication. Using the supernatant of the cell lysate (approximately 1.3 X 107 cpm), immunoprecipitation was carried out as described10).
Reverse Fibrin Zymography BAECgrown in 35-mmdishes were washed twice with buffer B and incubated in 750/xl of medium A at 37°C for 2 hours in the absence or presence of KOD. After washing, cells were removed by scraping in 1ml of buffer B and centrifuged. The resulting cell pellet was dissolved in 100^1 of buffer B containing 0.5% Triton X-100. The cell lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions. After electrophoresis, the gel was washed twice with 250ml of 2.5% Triton X-100 for 45minutes to remove SEPT. 1999 SDS, placed onto a fibrin-agar indicator geln) containing 0.2unit/ml UPA, and incubated at 37°C for 3-5 hours. The indicator gel was stained with 0.1% amide black in 30% methanol and 10% acetic acid and was destained in 30% methanol and 10% acetic acid.
Determination of PAI-1 Activity PAI-1 activity was determined as the inhibitory activity against UPAas follows. Active humanmelanomaPAI-1 (4.21jUg/ml) was preincubated with or without KODin 50Art of buffer D at 37°C for 15minutes. Subsequently, 25 jul of UPA (8 units/ml) in buffer D containing 20mg/ml bovine serum albumin were added and the mixture was incubated at 37°C for 30minutes. Then, remaining UPA activity was determined by adding 25ji\ of 0.4mM
Spectrozyme UK(in buffer D) to the mixture, followed
by further incubating at 37°C to measure changes in absorbance at 405nm. In the experiment by which reversibility of KODinhibition was examined, re-activated PAI-1 from human HT1080 cells (2.45/zg/ml) was preincubated in buffer E at 37°C for 30minutes in the absence or presence of KOD.The KOD-treated PAI-1 was assayed for UPAinhibition either directly or after dialysis against 4 m guanidine HC1 in phosphate-buffered saline, pH 7.3 containing 0. 1 mMdithiothreitol and 0.01% Tween 80 at 37°C for 4.5hours and then against 50mMsodium phosphate, pH 6.6, 500 mMNaCl, 0.1 mMdithiothreitol and 0.01% Tween 80 at 4°C for 16hours9). For UPAinhibition assay, aliquots of the treated PAI-1 (20ji\) was incubated with 10Art of UPA (75units/ml in buffer E) at 37°C for 15minutes.
Subsequently, the mixture received 20Art of Spectrozyme UK (0.25mM in buffer E) and changes in absorbance at 405 nm were measured at 37°C.
Results
The fibrinolytic activity of BAECwas determined by incubating the cells at 37°C for 6 hours in the absence or presence of KOD, followed by washing and further incubating the cells with plasminogen and a chromogenic plasmin substrate, S-2251. KODstimulated the activity at a concentration higher than 30 /im, and the activity doubled at -250/iM (Fig. 1A) . The elimination of plasminogen in the second incubation abolished the effect of KOD (data not shown), indicating that its effect was mediated by plasminogen activation. Stearic, oleic, linoleic and 3-hydroxyhexadecanoic acids failed to enhance, rather were inhibitory to, fibrinolytic activity at a concentration of 250~260/iM' (Fig. IB) , suggesting an essential role of the a,/?-unsaturated carbonyl function in the KODmolecule. To determine the contribution of plasminogen activators in the KODeffect, fibrinolytic activity was determined in the presence of anti-UPA and anti-tPA antibodies at concentrations inhibiting >95% of respective enzyme in a purified system. In control cells, activity was markedly reduced by anti-UPA but slightly by anti-tPA (Fig. 2 BAECwas significantly reduced (Fig. 3A) . Furthermore, when lysate from untreated BAECwas incubated with KOD in a cell-free conditions, the intensity of a lysisresistant band was markedly reduced as compared to that observed with lysate not incubated with KOD (Fig. 3B) , indicating a direct inhibition ofPAI-1 by KOD. Next, the effect of KODon human PAI-1 activity was examinedin a cell-free system using purified materials (Fig. 4) . In the first experiment, UPAwas incubated with human PAI-1 that had been preincubated with or without KOD, following which residual UPA activity was BAECwere incubated at 37°C for 6hours in the absence or presence of 270 /iM KOD.After washing, cells were incubated at 37°C for 10 minutes with buffer A containing none, anti-tPA IgG (2.85 /zg/ml) or antiuPA serum (215 /ig/ml). Subsequently each culture received plasminogen and S-2251. After further incubation at 37°C for 4 hours, changes in absorbance at 405nmwas measured. Each value represents the mean± S.D. from triplicate determinations. determined (Fig. 4A ). The residual UPA activity was reduced to 15%by PAI-1 that had not been treated with KOD.On the other hand, KOD-treated PAI-1 became less inhibitory. The residual UPA activity was increased to 50 and 67% by PAI-1 preincubated with KOD at concentrations of 300 and 600 jjm, respectively. KODdid not affect UPAactivity in the absence ofPAI-1. To examine whether KODinhibition of PAI-1 involved an inactivation or of an elevated conversion of active PAI-1 to latent analogue, active PAI-1 was incubated with KODand the treated PAI-1 was assayed for UPAinhibition before and after dialysis against guanidine HC1, which re-activates latent PAI-1. As shown in Fig. 4B , activity of KODtreated PAI-1 to inhibit UPAwas not restored even after dialysis against the denaturant; this demonstrated that an irreversible inactivation of PAI-1 occurred. SEPT. 1999 was subjected to SDS-PAGE on a 10% gel under reducing conditions. Subsequently, the gel was processed for reverse fibrin zymography. Lane 1, control; lane 2, KOD-treated. Arrowhead denotes the position of lysis-resistant band.
Discussion
KODincreases plasmin activity of BAEC.Although the KODeffect is not apparent in the absence of plasminogen and is blocked by anti-UPA, it enhances neither production nor activation of UPAin the cells. Further, KODis not stimulatory to urokinase-catalyzed plasminogen activation and the resulting plasmin activity in a purified system. On the other hand, PAI-1 activities both in BAECand in a purified system are markedly inhibited by KOD.From these results, it was concluded that KOD enhances fibrinolytic activity of BAEC, at least in part, by inhibiting PAI-1. PAI-1 is spontaneously converted to the latent form5), which can region (P15 to Pr) of the mobile reactive site loop4), which plays a role by being partially inserted into the^8-sheet A upon binding to a serine protease5). However, the amino acids 1 10-145 region, which participates in target protease binding15), contains a histidine and three lysine residues4).
Thus, it is suggested that KODmodification of one (or more) of these residues in the 110-145 region may be 
